significant demand for its services with substantial growth forecast from what is already estimated to be a $1bn market.

With up to 50% of global demand for drug and metabolite analysis coming from the U.S. Xceleron will invest up to $7.5m on the purchase of a new accelerator mass spectrometer (AMS) to carry out analysis on pharmaceutical drug candidates, new laboratories in Maryland and additional personnel. The new facilities will come on stream in late 2007, considerably increasing the company's testing capacity. By 2011 employee numbers are planned to rise to at least 150 and North American revenues to exceed $20m.

Professor Colin Garner, CEO of Xceleron commented: "The purchase of a second AMS instrument and the creation of a new U.S. AMS centre is a further step in ensuring that Xceleron remains the world's leading provider of AMS services to pharmaceutical and biotechnology companies. The publication of the Exploratory IND by the FDA1 in January this year has significantly increased Xceleron's business from the U.S., the world's largest pharmaceutical market and we have been quick to respond to this challenge."

For further information:
Xceleron Ltd Prof. Colin Garner, CEO,
Tel: +44 (0) 1904 561561
Scott Tarrant, Vice President,
Business Development for North America
T +1 240 361 1900

Xceleron's Gaithersburg office. The company occupies a 2000 sq. ft office suite in this building